Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.66 |
| ▸ | RGS12 | O14924 | 3/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesulergine SCHEMBL11415354 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL3143855 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL29408582 | 1.00 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL1321023 | 0.99 | HTR2B (0.98) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL677489 | 0.98 | HTR2B (0.96) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670412 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670405 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670418 | 0.88 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408974 | 0.81 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408971 | 0.81 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2118 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| US-20240226110-A1 | 5-HT2C AGONIST FOR USE IN TREATING CONDITIONS ASSOCIATED WITH CENTRAL HYPOVENTILATION | APNIMED, INC. (DELAWARE) | 2024-07-11 | — | — | US | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| WO-1999065563-A1 | ELECTRICALLY ASSISTED TRANSDERMAL METHOD AND APPARATUS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | GENETRONICS, INC. (US) | 1999-12-23 | — | — | WO | claimed |
| WO-1998042331-A1 | MEDIATION OF CIRCADIAN RHYTHMS | LUMINIS PTY. LIMITED (AU) | 1998-10-01 | — | — | WO | claimed |
| EP-0527835-B1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORP (US) | 1994-10-26 | — | — | EP | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| US-5190763-A | DOSAGE FORM INDICATED FOR THE MANAGEMENT OF ABNORMAL POSTURE, TREMOR AND INVOLUNTARY MOVEMENT | ALZA CORPORATION (US) | 1993-03-02 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| US-4225605-A | Ergolene or ergoline compounds for treating congestive heart failure | SANDOZ LTD. (CH) | 1980-09-30 | — | — | US | claimed |